A Multi-Institutional Analysis of the Effect of Positive Surgical Margins Following Robot-Assisted Partial Nephrectomy on Oncologic Outcomes.

Journal: Journal of endourology
Published Date:

Abstract

To determine the effect of positive surgical margins (PSMs) on oncologic outcomes following robot-assisted partial nephrectomy (RAPN) and to identify factors that increase the likelihood of adverse oncologic outcomes. A multi-institutional database of patients who underwent RAPN with complete follow-up data was used to compare recurrence-free survival (RFS) and overall survival (OS) between 42 (5.1%) patients with a PSM and 797 (94.9%) patients with a negative surgical margin. Analysis was performed with univariable and multivariable Cox proportional hazard regression models adjusting for confounding variables. A Kaplan-Meier method was used to evaluate the relationship between PSM and oncologic outcomes (RFS and OS), and the equality of the curves was assessed using a log-rank test. The rate of PSM was 5.1%. RFS at 12, 24, and 36 months was 97.8%, 95.2%, and 92.9%. OS at 12, 24, and 36 months was 98.6%, 97.7%, and 93.3%. PSM was not associated with worse RFS in both univariable and multivariable analyses (hazard ratio [HR] = 1.43; 95% confidence interval [CI] = 0.37, 5.55;  = 0.607). Factors associated with worse RFS include pT3a upstaging (HR = 4.97; 95% CI = 1.63, 15.12;  = 0.005), a higher Charlson comorbidity index (HR = 1.68; 95% CI = 1.20, 2.34;  = 0.002); and advanced clinical stage (cT1a cT1b, HR = 4.22; 95% CI = 1.84, 9.68;  = 0.001 cT2a, HR = 14.09; 95% CI = 3.85, 51.53;  < 0.001). PSM was not associated with worse OS in both univariable and multivariable analyses (HR = 0.87; 95% CI = 0.26, 2.94;  = 0.821). Higher R.E.N.A.L. nephrometry score was found to be associated with worse OS (HR = 1.26; 95% CI = 1.01, 1.57;  = 0.041). Given the absence of association between PSM and worse oncologic outcomes, patients with PSM following RAPN should be carefully monitored for recurrence rather than undergo immediate secondary intervention. As advanced clinical stage (cT1b, cT2a) and pathologic upstaging (pT3a) were independently associated with disease recurrence, their presence may warrant more attentive postoperative surveillance.

Authors

  • Michael B Rothberg
    Department of Urology, Wake Forest School of Medicine, Winston-Salem, North Carolina.
  • David J Paulucci
    Department of Urology, Icahn School of Medicine at Mount Sinai Hospital , New York, New York.
  • Kennedy E Okhawere
    Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Christopher R Reynolds
    Department of Urology, Wake Forest School of Medicine, Winston-Salem, North Carolina.
  • Ketan K Badani
    Department of Urology, Icahn School of Medicine at Mount Sinai Hospital , New York, New York.
  • Ronney Abaza
    OhioHealth Robotic Urologic and Cancer Surgery, Dublin Methodist Hospital, Dublin, Ohio.
  • Daniel Eun
    Department of Urology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA.
  • Akshay Bhandari
    Columbia University Division of Urology, Mount Sinai Medical Center, Miami Beach, Florida, USA.
  • James Porter
    Swedish Urology Group, Swedish Medical Center Seattle and Issaquah, Seattle, WA, USA.
  • Ashok K Hemal